



# Snapshot of the COVID-19 Vaccines

Clinical trials show that all available vaccines work extremely well at preventing COVID-19.

## Johnson & Johnson

Adenovirus (viral vector) vaccine

## Pfizer – BioNTech

mRNA vaccines

## Moderna

mRNA vaccines

## Novavax

Protein subunit vaccine

**How many doses do I need for a primary series?**

For most people **18 and older - 1 dose**

For most people **6 months-4 years - 3 doses**, 3 weeks after 1<sup>st</sup>, 8 weeks after 2<sup>nd</sup>. **The third dose is bivalent.**

For most people **6 months and older - 2 doses**, 4-8 weeks apart

For most people **12 and older - 2 doses**, 3-8 weeks apart

**You are fully protected 2 weeks after completing your primary series**

For people **18 and older with immunocompromise - 2 doses**, 1 dose of Johnson & Johnson, followed by a dose of an mRNA vaccine at least 4 weeks after first dose

For most people **5 and older -2 doses**, 3-8 weeks apart

For people **5 and older with immunocompromise - 3 doses**, second dose 3 weeks after first, third dose at least 4 weeks after the second

For people **6 months and older with immunocompromise - 3 doses**, second dose 4 weeks after first, third dose at least 4 weeks after second

For people **12 and older with immunocompromise - 2 doses**, second dose 3 weeks after the first

**How old do I have to be to get this vaccine?**

18 years or older

6 months or older

6 months or older

12 years or older

**When should I get a booster dose?**

2 months after your last dose for an updated mRNA booster - 18 years and older\*

2 months after your last dose for an updated mRNA booster – 6 months and older\*

2 months after your last dose for an updated mRNA booster – 6 months and older\*

2 months after your last dose for an updated mRNA booster - 12 years and older\*

**Which booster am I eligible for?**

Anyone 18 years and older is eligible for an updated Pfizer or Moderna booster\*

Anyone 6 months – 4 years old who completed a three dose original monovalent Pfizer primary series is eligible for an updated Pfizer booster

Anyone 6 months – 4 years old who completed a Moderna primary series is eligible for an updated Moderna booster

Anyone 12 years and older is eligible for an updated Pfizer or Moderna booster\*

*\*Some individuals 18 years and older may also be eligible to receive a Novavax booster 6 months after completing their primary series in certain circumstances. Please visit [doh.wa.gov/covidbooster](https://doh.wa.gov/covidbooster) for more information.*

Anyone 5 years old who completed a Pfizer primary series is eligible for an updated Pfizer booster

Anyone 6 years and older is eligible for an updated Moderna or Pfizer booster\*

Anyone 5 years and older is eligible for an updated Moderna or Pfizer booster\*

	<b>Johnson &amp; Johnson</b>	<b>Pfizer – BioNTech</b>	<b>Moderna</b>	<b>Novavax</b>
<b>What was the efficacy of the vaccine in the clinical trials?</b>	<p><b>74%</b> protection against any illness</p> <p><b>85%</b> protection against severe illness</p> <p><b>100%</b> protection against hospitalizations and death</p>	<p><b>95%</b> protection against any illness</p> <p><b>100%</b> protection against death</p>	<p><b>94%</b> protection against any illness</p> <p><b>100%</b> protection against death</p>	<p><b>90%</b> protection against any illness</p> <p><b>100%</b> protection against death</p>
<b>What are the ingredients?</b>	The vaccine contains the active ingredient of adenovirus, along with fat, salts, and sugars.	The vaccine contains the active ingredient of messenger RNA (mRNA), along with fat, salts, and sugars.	The vaccine contains the active ingredient of messenger RNA (mRNA), along with fat, salts, and sugars.	The vaccine contains the active ingredient of spike glycoprotein, along with fats, salts, and sugars.
<b>Who was included in clinical trials?</b>	<ul style="list-style-type: none"> <li>• 3.3% Asian</li> <li>• 9.5% American Indian or Alaska Native</li> <li>• 19.4% Black/African American</li> <li>• 45% Hispanic/Latinx</li> <li>• 0.2% Native Hawaiian or other Pacific Islander</li> <li>• 5.6% Multiple races</li> <li>• 59% White</li> </ul> <p>41% of global clinical trial participants had one or more underlying health conditions</p>	<ul style="list-style-type: none"> <li>• 4% Asian</li> <li>• 0.6% American Indian or Alaska Native</li> <li>• 10% Black/African American</li> <li>• 26% Hispanic/Latinx</li> <li>• 0.2% Native Hawaiian or other Pacific Islander</li> <li>• 3% Multiple races</li> <li>• 82% White</li> </ul> <p>46.2% of global trial participants had an underlying health condition. 34.8% of participants were obese.</p>	<ul style="list-style-type: none"> <li>• 5% Asian</li> <li>• 1% American Indian or Alaska Native</li> <li>• 10% Black/African American</li> <li>• 20% Hispanic/Latinx</li> <li>• 0.2% Native Hawaiian or other Pacific Islander</li> <li>• 2.1% “of other descent”</li> <li>• 79% White</li> </ul> <p>22% of global trial participants had one high-risk condition and 4% had two or more high-risk conditions</p>	<ul style="list-style-type: none"> <li>• 75% White</li> <li>• 12% Black/African American</li> <li>• 7% American Indian or Alaska Native</li> <li>• 22% Hispanic/Latinx</li> </ul> <p>95% of trial participants were high risk - Either &gt; 65 years with comorbidities or living or working conditions involving known frequent exposure to COVID-19 or densely populated circumstances</p>